Kayser K, Ziehms S, Kayser G, Andre S, Bovin N V, Dong X, Kaltner H, Gabius H J
Department of Pathology, Thoraxklinik, Amalienstr. 5, Heidelberg, D-69126, Germany.
Int J Oncol. 1998 May;12(5):1189-94. doi: 10.3892/ijo.12.5.1189.
Based upon the reasoning that protein-carbohydrate recognition is involved in diverse intercellular activities including growth control and cell motility 14 probes have been employed to characterize epitope presence in sections of 80 cases with operated lung carcinomas, 20 patients with mesothelioma, and 20 cases with non-malignant lung diseases. As parts of the innate immune system with supposed relevance for host defense the mannan-binding lectin (MBL) and serum amyloid P component (SAP) were employed. The naturally occurring immunoglobulin G fractions with selectivity for alphaa-galactosides (alpha+) and beta-galactosides (beta+) and their subfractions with enhanced target selectivity (alpha+beta-,alpha-beta+) allowed the monitoring of expression of reactive sites for these autoantibodies as a step to elucidate potential anti-tumor activity. Due to the diversity of cellular galactoside-containing glycoconjugates two galectins and a plant lectin were included. As a measure of receptor activities for carbohydrates, neoglycoconjugates with alpha-galactose, the B-disaccharide, the Forssman-disaccharide, and alpha-glucose as histochemically crucial ligand part were tested in addition to an antibody against heparin-binding lectin. Quantitative image analysis revealed significant differences between cases with small cell and non-small cell lung cancer for the plant lectin and one galectin, cases with non-tumorous lung disease and lung carcinoma for serum amyloid P component and the beta-galactoside-selective autoantibody fraction. Prognostic relevance was observed for the presence of glucose-specific sites in small cell lung cancer and meso-thelioma cases, and of galectin- and alpha-galactoside-selective immunoglobulin G fraction-binding sites in non-small cell lung cancer patients.
基于蛋白质 - 碳水化合物识别参与包括生长控制和细胞运动在内的多种细胞间活动这一推理,已使用14种探针来表征80例手术切除的肺癌、20例间皮瘤患者以及20例非恶性肺部疾病患者组织切片中的表位存在情况。作为与宿主防御可能相关的先天免疫系统的组成部分,使用了甘露聚糖结合凝集素(MBL)和血清淀粉样蛋白P成分(SAP)。对α - 半乳糖苷(α +)和β - 半乳糖苷(β +)具有选择性的天然存在的免疫球蛋白G组分及其具有增强靶标选择性的亚组分(α +β -,α -β +),可以监测这些自身抗体反应位点的表达,作为阐明潜在抗肿瘤活性的一个步骤。由于细胞含半乳糖苷糖缀合物的多样性,纳入了两种半乳糖凝集素和一种植物凝集素。作为碳水化合物受体活性的一种衡量方法,除了针对肝素结合凝集素的抗体外,还测试了以α - 半乳糖、B - 二糖、福斯曼二糖和α - 葡萄糖作为组织化学关键配体部分的新糖缀合物。定量图像分析显示,小细胞肺癌和非小细胞肺癌病例在植物凝集素和一种半乳糖凝集素方面存在显著差异,非肿瘤性肺部疾病和肺癌病例在血清淀粉样蛋白P成分和β - 半乳糖苷选择性自身抗体组分方面存在显著差异。在小细胞肺癌和间皮瘤病例中,葡萄糖特异性位点的存在以及在非小细胞肺癌患者中半乳糖凝集素和α - 半乳糖苷选择性免疫球蛋白G组分结合位点的存在具有预后相关性。